Physician profile
Hal Nathan Buch
NPI 1780649574
$9,841.22
in general payments reported to CMS, 2019-2025
20 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $459 · 2020: $181 · 2021: $8,516 · 2022: $33.49 · 2023: $212 · 2024: $323 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $8,376.72 | 2021 | |
| Abbvie INC. | $235.85 | 2019-2025 | |
| Qol Medical, LLC | $184.13 | 2019-2024 | Sucraid, Sucraid |
| Allergan, INC. | $169.31 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $130.45 | 2020-2024 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $90.68 | 2019-2024 | Entyvio |
| Celgene Corporation | $87.57 | 2021-2023 | Zeposia |
| Ucb, INC. | $78.03 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.38 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $63.80 | 2024 | Dupixent |
| Redhill Biopharma INC. | $47.69 | 2020-2021 | |
| Gilead Sciences, INC. | $46.72 | 2019-2020 | |
| Janssen Biotech, INC. | $46.54 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $41.94 | 2024 | |
| Alfasigma USA, INC. | $38.84 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $34.08 | 2025 | Ibsrela |
| Medtronic, INC. | $28.56 | 2023 | Gi Genius |
| Braintree Laboratories, INC. | $28.07 | 2021 | |
| Ferring Pharmaceuticals INC. | $22.64 | 2019 | |
| Madrigal Pharmaceuticals | $22.22 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Buch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.